Fecal microbiota transplantation in ulcerative colitis, a retrospective microbiome analysis

Marcel A. de Leeuw & Manuel X. Duval, GeneCreek

Contents

List of Figures

List of Tables

Fecal microbiota transplantation in ulcerative colitis, a retrospective microbiome analysis

Marcel A. de Leeuw & Manuel X. Duval, GeneCreek

Background. Inflammatory bowel disease (IBD) is a set of conditions characterized by non-infectious chronic inflammation of the gastrointestinal tract. These primarily include Crohn's disease (CD), ulcerative colitis (UC) and indeterminate colitis. Fecal microbiota transplantation (FMT) has proven to be an effective treatment for some patients with active UC. However, factors contributing to the individual response to FMT therapy remain to be uncovered. There is currently no procedure allowing to predict the patients' response and to select the most adequate donor(s).

Methods. The first available UC longitudinal FMT microbiome data sets were reanalyzed, with focus on species level changes in the microbiota, using state-of-the-art and in part proprietary 16S analysis routines.

Results. We found the microbiomes of UC and CD patients to have paucity of obligate anaerobes, which could be a consequence of oxidative stress. Microbiomes of UC FMT responders and responder donors have higher phylogenetic diversity and a higher proportion of aerobes and facultative anaerobes as compared to non-responders and non-responder donors. We found *Proteobacteria* to account for the major part of species found in increased relative abundance in responders. Sphingolipid producers were found among these species.

Implications. Our findings contribute to the establishment of selection criteria for UC FMT donor samples and composition guidelines for future synthetic microbial communities. Instead of replenishing missing obligate anaerobes, our results suggest that oxidative stress resistant *Proteobacteria* are important for the establishment of an anaerobic environment and a successful UC FMT therapy.

Introduction

The incidence and prevalence of inflammatory bowel disease (IBD) is increasing worldwide. It can affect people of all ages, including children and geriatric populations, and can impact all aspects of life. The Global number of cases of IBD reached 6.8 million in 2017, with the highest age-standardized prevalence rates in the U.S.A. and the U.K. [1]. IBD is characterized by non-infectious chronic inflammation of the gastrointestinal tract, and primarily includes Crohn's disease (CD), ulcerative colitis (UC) and indeterminate colitis [2]. Whereas CD can affect any part of the gastroesophageal tract from the mouth to the anus, UC is confined to the large bowel. Diagnosis of IBD relies on a combination of medical history, physical examination, laboratory testing, and endoscopy with biopsy [3]. Treatment goals for IBD are to minimize symptoms, improve quality of life, and minimize progression and complications of the disease. Most treatments for UC target the immune system through mediators of the inflammatory cascade [4], but a substantial proportion of UC patients continue to have inadequate disease control.

Over 230 genetic risk loci have been associated with IBD. The association of the nucleotide-binding oligomerization domain 2 (NOD2), an intracellular innate immune sensor of bacteria, remains the strongest association to date [5]. The microbiota of UC patients are characterized by reduced complexity with depletion of commensal *Firmicutes* and *Bacteroidetes* [6–11], which is reflected in IgG antibody composition [12]. Mucosal concentration of bacteria is markedly increased in IBD [13], which is further accentuated in UC [14].

Fecal microbiota transplantation (FMT) is a therapeutic procedure aimed at replacing dysbiotic microbiota with physiological/commensal species by the administration of filtered fecal material from a healthy donor into the intestinal tract of a patient [15]. A number of studies, including randomized controlled trials [16–20], suggest that FMT is effective in the treatment of active UC, for approximately one out of three patients. For FMT to be successful in complex immune diseases like UC, it is assumed that therapeutic microbes must colonize the recipient's intestinal tract and persist in sufficient quantity and for a long enough period of time to result in a clinical benefit. It is as yet unclear which donor- and recipient related factors contribute to a successful clinical response, although in one study, donor stool diversity reached significance [17]. Current consensus guidelines focus on reducing the risk of potentially transmittable disease [21].

We combined a series of relevant longitudinal microbiome studies, available in the form of raw 16S data, in order to increase statistical power and to address elementary microbiome composition pertaining to clinical endpoints.

Materials & Methods

The materials summarized in Table 1 have been made available as part of clinical trials. All datasets are longitudinal, with data points covering pre-FMT assessment and post-FMT follow-up. Only one available data set, SRP254202, was eliminated because of a high amount of non-specific priming. For the purpose of profiling ulcerative colitis and Crohn's disease microbiomes, we also used the published dataset listed in supplemental Table S1.

Table 1: Longitudinal UC FMT data sets used in the study. N: number of patients, n: number of samples, 16S: variable regions covered, *:unpublished.

BioProject	SRA	N	n	type	16S	publ.
PRJEB11841	ERP013257	27	172	stool	V4	[17]
PRJEB26474	ERP108465	81	158	biopsy	V1-V2	[19]
PRJEB26472	ERP108463	81	309	stool	V1-V2	[19]
PRJNA515212	SRP180003	7	42	stool	V3-V4	[22]
PRJEB33851	ERP116682	28	98	stool	V4	*
PRJNA475599	SRP198502	12	235	stool	V4	[23]
PRJNA380944	SRP102742	21	109	stool	V4	[24]
PRJNA438164	SRP135559	7	21	stool	V4	[25]
PRJNA388210	SRP108284	20	78	stool	V4	*
total		203	1,222			

Data analysis

Amplicon Sequence Variants (ASVs) were generated with the R Bioconductor package dada2 [26], version 1.12.1 with recommended parameters, involving quality trimming, discarding of sequences with N's, assembly of forward and reverse sequences and chimera removal, as described previously [27]. Further analysis involved multiple alignment with mafft, version 6.603b [28] and approximately-maximum-likelihood phylogenetic tree generation with FastTreeMP, version 2.1.11 [29], both with default settings.

Taxonomic classification of ASVs was performed by cur|sor, an in-house Python and R program using random forest based supervised learning on the Ribosomal Database Project (RDP) release 11.5. Phenotypic content of microbiomes was inferred using species-level taxonomic assignments only and an in-house phenotypic database which has been initiated with information from BacDive [30] and the IJSEM journal [31] and has been hand-curated since. Resulting classifications and microbiome phenotypes are available from the github repository https://github.com/GeneCreek/UC-manuscript in the form of Phyloseq R data objects.

Detection of responder and non-responder associated taxa was performed with negative binomial differential analysis implemented by the R Bioconductor package DESeq2 [32], using Wald significance tests and local fitting, requiring pAdj < 0.001.

Responder status classification was performed using the R package caret using the partial least squares (PLS) method with 10 fold cross-validation and sampling of subjects to account for multiple microbiomes per subject.

Ecological networks were computed using inverse covariance with SPIEC-EASI [33] as incorporated in the R Bioconductor package SpiecEasi, version 1.0.7, using default parameters. Community structure was detected using cluster_edge_betweenness as provided by the R package `igraph`.

The cladogram was generated by in-house R scripts using the R package ggtree, version 2.0.1. [34].

Full stack downstream analysis scripts covering the whole manuscript are available from https://github.com/GeneCreek/UC-manuscript.

Results

Dysbiosis in IMIDs

Data set SRP183770 contains biological replicates of stool samples collected from patients with Crohn's disease (CD; N = 20), ulcerative colitis (UC; N = 19), multiple sclerosis (MS; N = 19), and rheumatoid arthritis (RA; N = 21) versus healthy controls (HC; N = 23) [35]. We initiated our study by describing the distribution of two fecal microbiome phenotypes, the species diversity with the Shannon diversity index and the strict anaerobes proportion, in UC samples within the context of these other immune mediated inflammatory diseases (IMIDs), Fig. 1 respectively Fig. 2. The strict anaerobes proportion is calculated as the proportion of obligate anaerobes among anaerobes. The ranking of the IMID's diseases is the same according to these two metrics, with notably rheumatoid arthritis positioned between ulcerative colitis and Crohn's disease.

Figure 1: Species diversity in IMIDs. Data set SRP183770, 79 subjects, 201 samples. Numbers reflect Wilcoxon signed rank test continuity corrected p-values. HC: healthy controls, MS: multiple sclerosis, UC: ulcerative colitis, RA: rheumatiod artritis, CD: Crohn's disease

Figure 2: Strict anaerobes proportion in IMIDs. Numbers reflect Wilcoxon signed rank test continuity corrected p-values. HC: healthy controls, MS: multiple sclerosis, UC: ulcerative colitis, RA: rheumatiod artritis, CD; Crohn's disease

Several publications have reported dysbiosis in UC can be reduced through FMT. This principle is illustrated using data set SRP108284 (20 patients) and Chao

species richness in supplemental Fig. S1. The improvement reaches statistical significance in the samples collected in the second week after a single FMT, but washes out subsequently in the fourth week.

Just like species diversity, the strict anaerobe proportion can be modified through FMT, Fig. S2. The two donors used in study SRP198502 (7 patients) were selected based on fecal butyrate concentration [23] and had a high proportion of strict anaerobes.

Responder and non-responder patients

Combining the UC patients from all data sets for which responder/non-responder status was available in study metadata (ERP013257, SRP135559, ERP116682 and SRP102742 totaling 49 responders and non-responders to FMT), we tested several microbiome phenotypes in relation to the responder status, two of which reached significance: the phylogenetic diversity at screening and the oxygen tolerance post FMT, Fig. 3. The latter is computed as the relative abundance difference between aerobes and anearobes.

Figure 3: Patient microbiome phylogenetic diversity (left) and oxygen tolerance (right). Combination of data sets ERP013257, SRP135559, ERP116682 and SRP102742, 49 patients. Numbers reflect Wilcoxon signed rank test continuity corrected p-values. NR: nonresponders, RE: responders.

Responder and non-responder donors

Data set ERP013257 comprises 51 samples from 12 donors which are associated with either non-response, partial response or response to UC treatment with FMT [17]. We again tested several microbiome phenotypes, this time in relation to the responder donor status. The same covariates as for the patients, i.e. phylogenetic diversity and oxygen tolerance reached significance, Fig. 4. Plotting the relation between phylogenetic diversity and oxygen tolerance for donor samples, we found these are related and separate responder and non-responder associated donors, Fig. S3. Phylogenetic diversity shows important variance around the donor

means.

Figure 4: Donor microbiome features, data set ERP013257. 51 samples from 12 donors. Numbers reflect Wilcoxon signed rank test continuity corrected p-values. Donors are associated with NR: nonresponders, PR: partial responders, RE: responders.

Responder and non-responder associated taxa

Reusing the combined dataset of 49 responders and non-responders, we first projected class level differences in relative abundances between non-responders and responders, post-FMT samples only (n=169), Fig. S4 respectively S5. Table S2 provides taxa with differentially significant relative abundances at the class level, using DESeq analysis (pAdj<0.05).

Running the same set through DESeq analysis using species-level taxonomic classifications, we obtained 135 species with differential relative abundance (pAdj<0.001). Figure 5 provides a cladogram of responder and non-responder associated species.

Figure 5: Cladogram of responder and non-responder associated species. DESeq2 analysis result, using post-FMT samples only (n=169) from the 49 patient combined ERP013257, SRP135559, ERP116682 and SRP102742 dataset.

Predictive modeling applying the partial least squares (PLS) classifier with 10 fold cross validation

and 20 repeats using these species as input features returned a model predicting responders and non-responders with a median area under the curve of 0.751.

Figure 6: Ecological network of responder and non-responder associated species. Only species with interactions are displayed. Responder associations are based on positive log fold change in relative abundance. Co-exclusion is indicated in red.

The same DESeq detected species were used as input for unsupervised ecological network generation and clustering, Fig. 6. Clustering analysis of this network revealed the largest community (n=33) is exclusively responder associated, Table S3. These species are in majority *Proteobacteria* - gram-negative (30/33) aerobes or facultative aerobes (32/33) among which we found four *Sphingomondaceae* species, *Sphingopyxis ginsengisoli*, *Sphingobium subterraneum*, *Sphingomonas kwangyangensis* and *Sphingomonas melonis*. Also noteworthy is the presence of four methane metabolizers among the species associated with responder status, *Methylobacterium adhaesivum*, *Methylobacterium populi*, *Methylomonas methanica* and *Methyloversatilis universalis*. The remaining 22 responder associated species are a mixture of gram positive and gram negative species in majority anaerobes (15/22), Table S4.

We tested available donor samples (n=134) for the detectable presence of identified responder associated species. Only a minority (5/33) of *Proteobacteria* were found in donor samples, whereas on the opposite, a majority (17/22) of anaerobe species could be traced back to donor samples.

Discussion

Limitations. The majority of data sets used in this study are form 16S variable region V4 sequencing. Not all species can be resolved using this amplicon. A better alternative is the combined V3-V4 amplicon which can be sequenced using the same technology, with paired-end reads.

Proteobacteria including the ones we reported, have been reported as possible contaminants, especially when DNA extraction is performed on low biomass samples [36]. In this study, we have re-used previously sequenced stool datasets, a high biomass sample type and we performed differential analysis between responder and non-responder samples. There does not seem to be a valid reason why responder samples would be more impacted by reagent contamination, hence we do not believe detected species are contaminants.

Oxidative stress in UC. Oxidative stress has been proposed as a mechanism underlying the pathophysiology of CD [37] and has long been known as a pathogenic factor of UC [38]. If radical oxygen species (ROS) are released in the lumen, we may expect modulation of the microbiome composition. Indeed, we observe a decreased proportion of strict anaerobes in the microbiome composition of UC and CD samples, accompanied by loss of species diversity. The loss of obligate anaerobes in IBD has been reported previously [39]. Thus we postulate oxidative stress in IMIDs drives the decrease in obligate anaerobes, which results in the loss of microbial diversity and loss of function such as butyrate production.

Engraftment of aerobes and facultative anaerobes. However, it does not seem from our results that engraftment of obligate anaerobes is important for remission - their proportion increases in responders, but does not reach significance (results not shown). Rather, what seems important is the transfer of aerobes and facultative anaerobes, which we found increased in both responder-associated donor stool and in responder patient stool as compared to non-responders. In particular, we detected *Proteobacteria* in responders, with an important level of ecological network correlation suggesting formation of biofilms, which increase resistance to oxidative stress.

Proteobacteria are the third most abundant bacterial phylum in the human gut, after *Firmicutes* and *Bacteroidetes* [40] and are abundant in the environment. Thus *Proteobacteria* could emerge from donor samples but also from environmental sources including the FMT procedure itself.

Proteobacteria and immunomodulation. It has been shown that *Proteobacteria* are responsible for the major part of functional gut microbiome variation between individuals, including lipopolysaccharide (LPS) biosynthesis [41]. For instance, *Pseudomonas aeruginose* which we find associated with responders, produces highly variable LPS [42]. Toll like receptors TLR2, TLR4 and TLR9 are increased in expression in UC [43, 44] and have been proposed as a target in IBD [45]. Comparative analysis of metagenomic data from the Human Microbiome Project and healthy-donor samples indicates that TLR immune silencing via LPS is a microbe-intrinsic

feature in all healthy adults [46]. Thus the boost in LPS challenge from transplanted *Proteobacteria* could have an immunosuppressive effect.

Sphingolipids. It has been reported Bacteroides derived sphingolipids are depleted in IBD. These lipids are critical for maintaining intestinal homeostasis and symbiosis [47]. Our results suggest *Spingomonaceae* which we found associated with responder status, could provide such sphingolipids in the gut as well.

Proteobacteria as early re-colonizers. The increased presence of *Proteobacteria* has been associated with dysbiosis and disease, with two notable exceptions, Roux-en-Y bypass surgery and neonates [48]. Due to the abundance of oxygen in the neonatal gut, facultative aerobes are the first colonizers, most frequently represented by *Escherichia coli*, *Enterococcus fecalis* and *Enterococcus faecium* followed by *Klebsiella* and *Enterobacter* [49]. Their expansion leads to a habitat suitable for colonization by strict anaerobes, through consumption of oxygen, modification of the pH and production of carbon dioxide and nutrients [48]. Proteobacteria provide for in situ glutathione (GSH) production in the gut, possible mitigating the oxidative stress in the intestinal lining [50]. Thus in addition to potentially damping innate immune activation, *Proteobacteria* could provide a suitable recolonization environment for other bacteria in transplanted UC patients.

Prospects

Our findings can be used to rationalize selection of donor samples from stool banks. Quantitative real-time PCR evaluation of donor samples for α-, β- and γ-*Proteobacteria* is possible with universal primers [51, 52], for a relatively modest incremental cost. Moreover, post FMT follow-up could make use of the same tools and eventual additional FMT could be applied in case low quantity of *Proteobacteria* are found in patient stool. This approach could also provide necessary confirmation of the the presence of α-*Proteobacteria* which are not thought to be part of normal gut bacteria.

Conclusions

In conclusion, we found the microbiomes of UC and CD patients to have paucity of obligate anaerobes, which could be related to oxidative stress. Microbiomes of UC FMT responders and responder donors have higher phylogenetic diversity and a higher proportion of aerobes and facultative anaerobes as compared to non-responders and non-responder donors. We found *Proteobacteria* to account for the major part of species detected in increased relative abundance in responders. Sphingolipid producers were found among these species. Thus, instead of replenishing missing obligate anaerobes, our results suggest supplementing with more oxidative stress resistant *Proteobacteria*, which can be seen as a paradigm shift. These findings should

contribute to the establishment of selection criteria for UC FMT donor samples and composition guidelines for future synthetic microbial communities.

Declarations

Acknowledgements. The authors received no financial support for this study. The authors acknowledge the contributions to the Short Read Archive made by the respective institutions and acknowledge scientific journals for enforcing this practice.

Conflict of interest. The authors have no conflict of interests related to this publication.

Authors' contributions. Study design, data collection, data analysis and writing of the manuscript (ML); data analysis and writing of the manuscript (MD).

Bibliography

[1] GBD 2017 IBD Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Gastroenterology & Hepatology*, 5(1):17–30, January 2020. doi: 10.1016/S2468-1253(19)30333-4.

[2] Barbara A Hendrickson, Ranjana Gokhale, and Judy H Cho. Clinical aspects and pathophysiology of inflammatory bowel disease. *Clinical Microbiology Reviews*, 15(1):79–94, January 2002. doi: 10.1128/cmr.15.1.79-94.2002.

[3] Tomoko Sairenji, Kimberly L Collins, and David V Evans. An Update on Inflammatory Bowel Disease. *Primary care*, 44(4):673–692, December 2017. doi: 10.1016/j.pop.2017.07.010.

[4] Grainne Holleran, Loris Lopetuso, Valentina Petito, Cristina Graziani, Gianluca Ianiro, Deirdre McNamara, Antonio Gasbarrini, and Franco Scaldaferri. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. *International journal of molecular sciences*, 18(10), September 2017. doi: 10.3390/ijms18102020.

[5] Ashleigh Goethel, Kenneth Croitoru, and Dana J Philpott. The interplay between microbes and the immune response in inflammatory bowel disease. *The Journal of physiology*, 596(17):3869–3882, September 2018. doi: 10.1113/JP275396.

[6] Daniel N Frank, Allison L St Amand, Robert A Feldman, Edgar C Boedeker, Noam Harpaz, and Norman R Pace. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *PNAS*, 104(34): 13780–13785, August 2007. doi: 10.1073/pnas.0706625104.

[7] Shadi Sepehri, Roman Kotlowski, Charles N Bernstein, and Denis O Krause. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. *Inflammatory Bowel Diseases*, 13(6):675–683, June 2007. doi: 10.1002/ibd. 20101.

[8] Samah O Noor, Karyn Ridgway, Louise Scovell, E Katherine Kemsley, Elizabeth K Lund, Crawford Jamieson, Ian T Johnson, and Arjan Narbad. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. *BMC gastroenterology*, 10(1):134–9, November 2010. doi: 10.1186/1471-230X-10-13.

[9] Mirjana Rajilić-Stojanović, Fergus Shanahan, Francisco Guarner, and Willem M de Vos. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. *Inflammatory Bowel Diseases*, 19(3):481–488, March 2013. doi: 10.1097/MIB. 0b013e31827fec6d.

[10] Fei Sjöberg, Cecilia Barkman, Intawat Nookaew, Sofia Östman, Ingegerd Adlerberth, Robert Saalman, and Agnes E Wold. Low-complexity microbiota in the duodenum of children with newly diagnosed ulcerative colitis. *PLoS ONE*, 12(10), 2017. doi: 10.1371/journal.pone.0186178.

[11] Hengameh Chloé Mirsepasi-Lauridsen, Katleen Vrankx, Jørgen Engberg, Alice Friis-Møller, Jørn Brynskov, Inge Nordgaard-Lassen, Andreas Munk Petersen, and Karen Angeliki Krogfelt. Disease-Specific Enteric Microbiome Dysbiosis in Inflammatory Bowel Disease. *Frontiers in medicine*, 5, 2018. doi: 10.3389/fmed.2018.00304.

[12] E Furrie, S Macfarlane, J H Cummings, and G T Macfarlane. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. *BMJ Gut*, 53(1):91–−98, January 2004. doi: 10.1136/gut. 53.1.91.

[13] Alexander Swidsinski, Axel Ladhoff, Annelie Pernthaler, Sonja Swidsinski, Vera Loening-Baucke, Marianne Ortner, Jutta Weber, Uwe Hoffmann, Stefan Schreiber, Manfred Dietel, and Herbert Lochs. Mucosal flora in inflammatory bowel disease. *Gastroenterology*, 122(1):44–54, January 2002. doi: 10. 1053/gast.2002.30294.

[14] Rodrigo Bibiloni, Marco Mangold, Karen L Madsen, Richard N Fedorak, and Gerald W Tannock. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. *Journal of medical microbiology*, 55(Pt 8):1141–1149, August 2006.

[15] Faming Zhang, Bota Cui, Xingxiang He, Yuqiang Nie, Kaichun Wu, Daiming Fan, and FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. *Protein & cell*, 9(5):462–473, May 2018. doi: 10.1007/s13238-018-0541-8.

[16] Paul Moayyedi, Michael G Surette, Peter T Kim, Josie Libertucci, Melanie Wolfe, Catherine Onischi, David Armstrong, John K Marshall, Zain Kassam, Walter Reinisch, and Christine H Lee. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology*, 149(1):102–109.e6, July 2015. doi: 10.1053/j.gastro.2015.04. 001.

[17] P Kump, P Wurm, H P Gröchenig, H Wenzl, W Petritsch, B Halwachs, M Wagner, V Stadlbauer, A Eherer, K M Hoffmann, A Deutschmann, G Reicht, L Reiter, P Slawitsch, G Gorkiewicz, and C Högenauer. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. *Alimentary Pharmacology & Therapeutics*, 47(1):67–77, October 2017. doi: 10.1111/apt.14387.

[18] Sudarshan Paramsothy, Michael A Kamm, Nadeem O Kaakoush, Alissa J Walsh, Johan van den Bogaerde, Douglas Samuel, Rupert W L Leong, Susan Connor, Watson Ng, Ramesh Paramsothy, Wei Xuan, Enmoore Lin, Hazel M Mitchell, and Thomas J Borody. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet (London, England)*, 389(10075):1218–1228, March 2017. doi: 10.1016/S0140-6736(17)30182-4.

[19] Sudarshan Paramsothy, Shaun Nielsen, Michael A Kamm, Nandan P Deshpande, Jeremiah J Faith, Jose C Clemente, Ramesh Paramsothy, Alissa J Walsh, Johan van den Bogaerde, Douglas Samuel, Rupert W L Leong, Susan Connor, Watson Ng, Enmoore Lin, Thomas J Borody, Marc R Wilkins, Jean-Frederic Colombel, Hazel M Mitchell, and Nadeem O Kaakoush. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. *Gastroenterology*, 156(5):1440–1454.e2, April 2019. doi: 10.1053/j.gastro.2018.12.001.

[20] Samuel P Costello, Patrick A Hughes, Oliver Waters, Robert V Bryant, Andrew D Vincent, Paul Blatchford, Rosa Katsikeros, Jesica Makanyanga, Melissa A Campaniello, Chris Mavrangelos, Carly P Rosewarne, Chelsea Bickley, Cian Peters, Mark N Schoeman, Michael A Conlon, Ian C Roberts-Thomson, and Jane M Andrews. Effect of Fecal Microbiota Transplantation on 8-Week Remission in

Patients With Ulcerative Colitis: A Randomized Clinical Trial. *JAMA*, 321(2):156–164, January 2019. doi: 10.1001/jama.2018.20046.

[21] Thomas J Borody and Annabel Clancy. Fecal microbiota transplantation for ulcerative colitis-where to from here? *Translational gastroenterology and hepatology*, 4, 2019. doi: 10.21037/tgh.2019.06.04.

[22] F Cold, P D Browne, S Günther, S I Halkjaer, A M Petersen, Z Al-Gibouri, L H Hansen, and A H Christensen. Multidonor FMT capsules improve symptoms and decrease fecal calprotectin in ulcerative colitis patients while treated - an open-label pilot study. *Scandinavian journal of gastroenterology*, 54 (3):289–296, March 2019. doi: 10.1080/00365521. 2019.1585939.

[23] Nathaniel D Chu, Jessica W Crothers, Le T T Nguyen, Sean M Kearney, Mark B Smith, Zain Kassam, Cheryl Collins, Ramnik Xavier, Peter L Moses, and Eric J Alm. Dynamic colonization of microbes and their functions after fecal microbiota transplantation for inflammatory bowel disease. *bioRxiv*, 2: 17004–36, January 2020. doi: 10.1101/649384.

[24] Alka Goyal, Andrew Yeh, Brian R Bush, Brian A Firek, Leah M Siebold, Matthew Brian Rogers, Adam D Kufen, and Michael J Morowitz. Safety, Clinical Response, and Microbiome Findings Following Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, 24(2):410–421, January 2018. doi: 10. 1093/ibd/izx035.

[25] David J Nusbaum, Fengzhu Sun, Jie Ren, Zifan Zhu, Natalie Ramsy, Nicholas Pervolarakis, Sachin Kunde, Whitney England, Bei Gao, Oliver Fiehn, Sonia Michail, and Katrine Whiteson. Gut microbial and metabolomic profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients. *FEMS Microbiology Ecology*, 94(9):129, September 2018. doi: 10.1093/femsec/fiy133.

[26] McMurdie, Paul J, Rosen, Michael J, Han, Andrew W, Johnson, Amy Jo A, Holmes, Susan P, and Callahan, Benjamin J. DADA2: High-resolution sample inference from Illumina amplicon data. *Nature Methods*, pages 1–7, May 2016. doi: 10.1038/nmeth.3869.

[27] Ben J Callahan, Kris Sankaran, Julia A Fukuyama, Paul J McMurdie, and Susan P Holmes. Bioconductor Workflow for Microbiome Data Analysis: from raw reads to community analyses. *F1000Research*, 5, 2016. doi: 10.12688/f1000research.8986.2.

[28] Kazutaka Katoh, George Asimenos, and Hiroyuki Toh. Multiple alignment of DNA sequences with MAFFT. *Methods in molecular biology (Clifton, N.J.)*, 537(Suppl 5):39–64, 2009. doi: 10.1007/ 978-1-59745-251-9_3.

[29] Price, Morgan N, Dehal, Paramvir S, and Arkin, Adam P. FastTree 2–approximately maximum-likelihood trees for large alignments. *PLoS ONE*, 5 (3):e9490, March 2010. doi: 10.1371/journal.pone. 0009490.

[30] Lorenz Christian Reimer, Anna Vetcininova, Joaquim Sardà Carbasse, Carola Söhngen, Dorothea Gleim, Christian Ebeling, and Jörg Overmann. BacDive in 2019: bacterial phenotypic data for High-throughput biodiversity analysis. *Nucleic acids research*, 47(D1):D631–D636, January 2019. doi: 10.1093/nar/gky879.

[31] Albert Barberán, Hildamarie Caceres Velazquez, Stuart Jones, Noah Fierer, and Steven J Hallam. Hiding in Plain Sight: Mining Bacterial Species Records for Phenotypic Trait Information. *mSphere*, 2(4): e00237–17, August 2017. doi: 10.1128/mSphere. 00237-17.

[32] Michael I Love, Wolfgang Huber, and Simon Anders. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology*, 15(12):550, 2014. doi: 10.1186/ s13059-014-0550-8.

[33] Zachary D Kurtz, Christian L Müller, Emily R Miraldi, Dan R Littman, Martin J Blaser, and Richard A Bonneau. Sparse and compositionally robust inference of microbial ecological networks. *PLoS Computational Biology*, 11(5):e1004226, May 2015. doi: 10.1371/journal.pcbi.1004226.

[34] Guangchuang Yu. Using ggtree to Visualize Data on Tree-Like Structures. *Current Protocols in Bioinformatics*, 69(1):96, March 2020. doi: 10.1002/cpbi.96.

[35] Jessica D Forbes, Chih-Yu Chen, Natalie C Knox, Ruth-Ann Marrie, Hani El-Gabalawy, Teresa de Kievit, Michelle Alfa, Charles N Bernstein, and Gary Van Domselaar. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? *Microbiome*, 6(1):221–15, December 2018. doi: 10.1186/s40168-018-0603-4.

[36] Susannah J Salter, Michael J Cox, Elena M Turek, Szymon T Calus, William O Cookson, Miriam F Moffatt, Paul Turner, Julian Parkhill, Nicholas J Loman, and Alan W Walker. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. *BMC Biology*, 12(1):87, November 2014. doi: 10.1186/s12915-014-0087-z.

[37] Mohammed A Alzoghaibi. Concepts of oxidative stress and antioxidant defense in Crohn's disease. *World journal of gastroenterology : WJG*, 19(39): 6540–6547, October 2013. doi: 10.3748/wjg.v19. i39.6540.

[38] Zhiqi Wang, Sai Li, Yu Cao, Xuefei Tian, Rong Zeng, Duan-Fang Liao, and Deliang Cao. Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer. *Oxidative medicine and cellular longevity*, 2016(3):9875298–15, 2016. doi: 10.1155/2016/9875298.

[39] Jason Lloyd-Price, Cesar Arze, Ashwin N Ananthakrishnan, Melanie Schirmer, Julian Avila-Pacheco, Tiffany W Poon, Elizabeth Andrews, Nadim J Ajami, Kevin S Bonham, Colin J Brislawn, David Casero, Holly Courtney, Antonio González, Thomas G Graeber, A Brantley Hall, Kathleen Lake, Carol J Landers, Himel Mallick, Damian R Plichta, Mahadev Prasad, Gholamali Rahnavard, Jenny Sauk, Dmitry Shungin, Yoshiki Vázquez-Baeza, Richard A White, IBD-MDB Investigators, Jonathan Braun, Lee A Denson, Janet K Jansson, Rob Knight, Subra Kugathasan, Dermot P B McGovern, Joseph F Petrosino, Thaddeus S Stappenbeck, Harland S Winter, Clary B Clish, Eric A Franzosa, Hera Vlamakis, Ramnik J Xavier, and Curtis Huttenhower. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature*, 569(7758):655–662, May 2019. doi: 10.1038/s41586-019-1237-9.

[40] Fredrik Bäckhed, Ruth E Ley, Justin L Sonnenburg, Daniel A Peterson, and Jeffrey I Gordon. Host-bacterial mutualism in the human intestine. *Science*, 307(5717):1915–1920, March 2005. doi: 10.1126/science.1104816.

[41] Patrick H Bradley and Katherine S Pollard. Proteobacteria explain significant functional variability in the human gut microbiome. *Microbiome*, 5(1):36–23, March 2017. doi: 10.1186/s40168-017-0244-z.

[42] Gerald B Pier. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. *International Journal of Medical Microbiology*, 297(5):277–295, September 2007. doi: 10.1016/j.ijmm.2007.03.012.

[43] Yan Tan, Kai-Fang Zou, Wei Qian, Sheng Chen, and Xiao-Hua Hou. Expression and implication of toll-like receptors TLR2, TLR4 and TLR9 in colonic mucosa of patients with ulcerative colitis. *Journal of Huazhong University of Science and Technology.*, 34(5):785–790, October 2014. doi: 10.1007/s11596-014-1353-6.

[44] Yujing Fan and Bingrong Liu. Expression of Toll-like receptors in the mucosa of patients with ulcerative colitis. *Experimental and therapeutic medicine*, 9(4):1455–1459, April 2015. doi: 10.3892/etm.2015.2258.

[45] Nastaran Kordjazy, Arvin Haj-Mirzaian, Arya Haj-Mirzaian, Mohammad Mojtaba Rohani, Erwin W Gelfand, Nima Rezaei, and Amir Hossein Abdolghaffari. Role of toll-like receptors in inflammatory bowel disease. *Pharmacological research*, 129:204–215, March 2018. doi: 10.1016/j.phrs.2017.11.017.

[46] Eva d'Hennezel, Sahar Abubucker, Leon O Murphy, and Thomas W Cullen. Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling. *mSystems*, 2(6):59, November 2017. doi: 10.1128/mSystems.00046-17.

[47] Eric M Brown, Xiaobo Ke, Daniel Hitchcock, Sarah Jeanfavre, Julian Avila-Pacheco, Toru Nakata, Timothy D Arthur, Nadine Fornelos, Cortney Heim, Eric A Franzosa, Nicki Watson, Curtis Huttenhower, Henry J Haiser, Glen Dillow, Daniel B Graham, B Brett Finlay, Aleksandar D Kostic, Jeffrey A Porter, Hera Vlamakis, Clary B Clish, and Ramnik J Xavier. Bacteroides-Derived Sphingolipids Are Critical for Maintaining Intestinal Homeostasis and Symbiosis. *Cell host & microbe*, 25(5):668–680.e7, May 2019. doi: 10.1016/j.chom.2019.04.002.

[48] Na-Ri Shin, Tae Woong Whon, and Jin-Woo Bae. Proteobacteria: microbial signature of dysbiosis in gut microbiota. *Trends in biotechnology*, 33(9):496–503, September 2015. doi: 10.1016/j.tibtech.2015.06.011.

[49] Federica Guaraldi and Guglielmo Salvatori. Effect of breast and formula feeding on gut microbiota shaping in newborns. *Frontiers in cellular and infection microbiology*, 2:94, 2012. doi: 10.3389/fcimb.2012.00094.

[50] Lluis Masip, Karthik Veeravalli, and George Georgiou. The many faces of glutathione in bacteria. *Antioxidants & Redox Signaling*, 8(5-6):753–762, May 2006. doi: 10.1089/ars.2006.8.753.

[51] Tristano Bacchetti De Gregoris, Nick Aldred, Anthony S Clare, and J Grant Burgess. Improvement of phylum- and class-specific primers for real-time PCR quantification of bacterial taxa. *Journal of Microbiological Methods*, 86(3):351–356, September 2011. doi: 10.1016/j.mimet.2011.06.010.

[52] Yun-Wen Yang, Mang-Kun Chen, Bing-Ya Yang, Xian-Jie Huang, Xue-Rui Zhang, Liang-Qiang He, Jing Zhang, and Zi-Chun Hua. Use of 16S rRNA Gene-Targeted Group-Specific Primers for Real-Time PCR Analysis of Predominant Bacteria in Mouse Feces. *Applied and Environmental Microbiology*, 81(19):6749–6756, October 2015. doi: 10.1128/AEM.01906-15.